News

GSK's asthma drug wins FDA approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
Health and Me on MSN11h
FDA Greenlights Nucala as New Treatment for COPD
FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...
pharmaphorum1d
GSK claims first approval for Nucala in COPD
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
STAT1d
GSK drug’s new approval sets up competition with Dupixent
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.
The American Journal of Managed Care1d
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
BioSpace1d
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
Pharmaceutical Technology4d
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...
GSK (LSE:GSK) Secures FDA Approval For COPD Treatment, Eyes European Nod For Blenrep
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence. Meanwhile, the Committee for Medicinal Products for Human Use recommended Blenrep ...